Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline.
‘Man flu’ is real, according to an exclusive trial carried out by pharmaphorum and based on a new methodology that could revolutionise research into some of the world’s most challenging dis
A European Medicines Agency advisory panel has recommended a conditional approval for Zynteglo, bluebird bio’s lead gene therapy for thalassemia, a rare blood disorder.
Atai Life sciences has closed a $43 million second-round financing that will help it advance new medicines for mental illnesses derived from compounds in illicit drugs.